A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

144

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Azeliragon
DRUG: Placebo

Sponsor

The University of Texas Medical Branch, Galveston